Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Versus Rituximab in PR3-ANCA-Associated Vasculitis
NCT05376319Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Mayo Clinic. Started Jun 2023; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05376319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376319.